Nuvilex Moves Closer to Head to Head With Eli Lilly and Company in Phase III Clinical Trials

Published: Jul 25, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nuvilex, Inc. Moves Closer to Head to Head With Eli Lilly in Phase III Clinical Trials

NEW YORK, NY--(Marketwired - July 25, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly's blockbuster cancer drug, Gemzar, and doing so with the knowledge that in two independent mid-phase clinical trials, the company's treatment involving its proprietary living cell encapsulation technology has outperformed the pharmaceutical giant. Nuvilex has produced better results when compared to historical data for Gemzar, and now the company is ready to use real time, head to head data to prove its treatment is superior to Eli Lilly's.

Last week Nuvilex moved one step closer to going head to head with Eli Lilly when it completed a blockbuster acquisition. The deal strengthened the company's hand dramatically, and now Nuvilex owns exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment that it will use to go head to head with Eli Lilly. Additionally, these licenses include worldwide rights to utilize the live-cell encapsulation platform technology to develop treatments for any and all cancer types, regardless of the cell type encapsulated.

About $25-million have been invested in two Phase II clinical trials in patients with advanced, inoperable pancreatic cancer using the combination of the widely used anti-cancer drug, ifosfamide, together with encapsulated cells capable of converting the ifosfamide into its "cancer-killing" form and in pre-clinical studies of other applications for the technology. In addition, Nuvilex has put almost another $2-million into furthering the development of the cell encapsulation technology itself.

This investment for the Silver Spring, Maryland-based biotech was made for just this challenge. Gemzar, the standard single drug for pancreatic cancer patients equates to about $1.4-billion annually to Eli Lilly. There is a lot at stake in the future Phase III clinical trials -- for Eli Lilly, for Nuvilex and for cancer patients who are looking for a better treatment than the current single agent "gold standard."

One has to imagine with the data already on the table that this is a head to head matchup that Nuvilex greatly anticipates while Eli Lilly might dread the end results.

Continue reading this article at

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors. For more information:

Stock Market Media Group
Email Contact
(646) 397-4020

Digg this    Bookmark with    Add to Newsvine


Help employers find you! Check out all the jobs and post your resume.

Back to news